Industry
Biotechnology
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Loading...
Open
1.11
Mkt cap
33M
Volume
868K
High
1.12
P/E Ratio
-0.50
52-wk high
22.22
Low
1.09
Div yield
N/A
52-wk low
0.87
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:39 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:37 pm
Portfolio Pulse from Benzinga Newsdesk
July 05, 2024 | 2:58 pm
Portfolio Pulse from Benzinga Insights
June 14, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 3:51 pm
Portfolio Pulse from Benzinga Insights
April 04, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
April 02, 2024 | 6:05 pm
Portfolio Pulse from Benzinga Newsdesk
April 01, 2024 | 1:13 pm
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 8:49 pm
Portfolio Pulse from Avi Kapoor
February 13, 2024 | 1:08 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.